|
| 36150045 | Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide. | Journal of acquired immune deficiency syndromes (1999) | 2023 |
| 35013081 | Aging, trends in CD4+/CD8+ cell ratio, and clinical outcomes with persistent HIV suppression in a dynamic cohort of ambulatory HIV patients. | AIDS | 2022 |
| 32668455 | Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. | Clinical Infectious Diseases | 2021 |
| 32724674 | Real-World Experience with Dolutegravir-Based Two-Drug Regimens. | AIDS Research and Treatment | 2020 |
| 31689341 | Chlamydia and Gonorrhea Incidence and Testing Among Patients in the Human Immunodeficiency Virus Outpatient Study (HOPS), 2007-2017. | Clinical Infectious Diseases | 2020 |
| 32357195 | It made me more confident that I have it under control: Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain. | PLoS ONE | 2020 |
| 32455145 | The HIV Outpatient Study-25 Years of HIV Patient Care and Epidemiologic Research. | Open Forum Infectious Diseases | 2020 |
| 31764098 | Non-AIDS comorbidity burden differs by sex, race, and insurance type in aging adults in HIV care. | AIDS | 2019 |
| 29794828 | Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. | AIDS | 2018 |
| 29925489 | Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas | Lancet HIV,The | 2018 |
| 29688270 | Risk Factors and Incidence of Syphilis in Human Immunodeficiency Virus (HIV)-Infected Persons: The HIV Outpatient Study, 1999-2015. | Clinical Infectious Diseases | 2018 |
| 29316797 | Disparities in HIV Viral Load Suppression by Race/Ethnicity Among Men Who Have Sex with Men in the HIV Outpatient Study. | AIDS Research and Human Retroviruses | 2018 |
| 28219610 | Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. | Lancet HIV,The | 2017 |
| 28689453 | Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. | HIV Clin Trials | 2017 |
| 28416195 | Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. | Lancet HIV,The | 2017 |
| 27036991 | Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ | Lancet HIV,The | 2016 |
| 26188010 | Five Antiretroviral Drug Class-Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection. | Journal of the International Association of Providers of AIDS Care | 2015 |
| 25296097 | Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy. | Journal of acquired immune deficiency syndromes (1999) | 2015 |
| 24710918 | Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. | HIV Clinical Trials | 2014 |
| 24586911 | HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing. | PLoS One | 2014 |
| 23449713 | Considerations on the new nevirapine: switching patients from twice-daily to once-daily. | Journal of the International Association of Providers of AIDS Care | 2013 |
| 22136068 | Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200â¿¿mg twice daily to nevirapine extended release 400â¿¿mg once daily (TRANxITION). | HIV Medicine | 2012 |
| 22611484 | Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008. | AIDS Research and Treatment | 2012 |
| 23134624 | ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. | HIV Clinical Trials | 2012 |
| 21684853 | Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients. | HIV Clin Trials | 2011 |
| 21051598 | The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. | Science | 2010 |
| 19898218 | Virologic and immunologic activity of PegIntron in HIV disease. | AIDS | 2009 |
| 19357529 | Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) | 2009 |
| 19214123 | Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. | J Acquir Immune Defic Syndr | 2009 |
| 18260759 | Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. | Journal of Infectious Diseases | 2008 |
| 18753116 | Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. | HIV Clinical Trials | 2008 |
| 18090054 | Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. | AIDS | 2007 |
| 17413684 | Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. | AIDS | 2007 |
| 17491001 | Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006. | Journal of Antimicrobial Chemotherapy | 2007 |
| 17243069 | Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. | Clin Infect Dis | 2007 |
| 16893323 | Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. | AIDS Patient Care and STDs | 2006 |
| 17162316 | Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. | HIV Clinical Trials | 2006 |
| 16276421 | HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. | Journal of Clinical Investigation | 2005 |
| 14699460 | Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. | Clinical Infectious Diseases | 2004 |
| 15220700 | Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. | Journal of acquired immune deficiency syndromes (1999) | 2004 |
| 12514413 | Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) | 2003 |
| 12480430 | Protease inhibitors and cardiovascular outcomes in patients with HIV-1. | Lancet, The | 2002 |
| 12370502 | Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. | AIDS | 2002 |
| 11734634 | Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. | Proc Natl Acad Sci U S A | 2001 |
| 11504960 | Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. | AIDS | 2001 |
| 10836864 | Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy. | Journal of Infectious Diseases | 2000 |
| 10475534 | Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). | Annals of Epidemiology | 1999 |
| 16021878 | An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice. | Antiviral Therapy | 1999 |
| 10023903 | HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. | Lancet | 1999 |
| 10555103 | Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. | AIDS Res Hum Retroviruses | 1999 |